




Figure S1 Study flow chart.




Figure S2 (A,B) Survival analysis between the anti-angiogenic therapy plus immune checkpoint inhibitors (ICIs) group and the chemotherapy plus ICIs group.




Figure S3 PFS (A) and OS (B) in SMARCA4-deficient NSCLC patients treated with immunotherapy versus without immunotherapy for first-line and PFS (C) and OS (D) in SMARCA4-deficient UT patients treated with immunotherapy versus without immunotherapy for first-line.